A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Exclusion Criteria

• •Use of an investigational / non-registered product other than the study vaccines within 30 days before study vaccination or planned use during study period.
• •Planned administration or administration of a licensed vaccine within 30 days before study vaccination.
• •Prior receipt of 2010/2011 influenza vaccine.
• •Receipt of any investigational or approved influenza vaccine within six months of the first study visit.
• •Any known or suspected allergy to any constituent of influenza vaccines ; a history of anaphylactic-type reaction to constituent of vaccine; or a history of severe adverse reaction to a previous influenza vaccine.
• •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
• •History of Guillain-Barre syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
• •Presence or evidence of substance abuse or of neurological or psychiatric diagnoses which, even if clinically stable, are deemed by the investigator to render the potential subject unable / unlikely to provide accurate safety reports.
• •Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, based on history and physical examination.
• •Presence of significant uncontrolled chronic medical or neuropsychiatric illness, based on history and physical examination
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• •Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin
• •Chronic administration of immunosuppressants or other immune-modifying drugs within 3 months prior to the first vaccine/product dose.
• •Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
• •Pregnant or lactating female.
• •Fever at the time of enrolment.
• •Acute disease at the time of enrolment
• •Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.